Drug
CF101 clinical trials
Also written CF101 and IB-MECA.
- studies test it
- 15
- open now
- 2
- in phase 3
- 5
- first study started
- 2006
Keep track of what changes. Save the CF101 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2007 (2)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 1 |
| 2010 | 2 |
| 2011 | 2 |
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 1 |
| 2021 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 11
- Phase 3
- 5
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 0
Studies
Open first, then newest update. How each study uses CF101 is read from its arms, and is right about nine times in ten.
Testing it · 15
- An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe SyndromeNot yet recruitingPhase 2Can-Fite BioPharmaNCT07410455Written as Piclidenoson
- A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and EfficacyNot yet recruitingPhase 3Can-Fite BioPharmaNCT06643260Written as piclidenoson
- Oral CF101 and Methotrexate Treatment in Rheumatoid Arthritis PatientsCompletedPhase 2Can-Fite BioPharmaNCT00280917Written as CF101
- Safety and Efficacy Study of CF101 to Treat PsoriasisCompletedPhase 2Can-Fite BioPharmaNCT00428974Written as CF101 1mg
- Trial of CF101 to Treat Patients With Dry Eye DiseaseCompletedPhase 3Can-Fite BioPharmaNCT01235234Written as CF101
- CF101 Therapy in Patients With Moderate-to-severe Plaque PsoriasisCompletedPhase 3Can-Fite BioPharmaNCT03168256Written as CF101 2mg
- Oral CF101 Tablets Treatment in Patients With Rheumatoid ArthritisCompletedPhase 2Can-Fite BioPharmaNCT01034306Written as CF101
- Safety and Efficacy of Daily CF101 Administered Orally in Subjects With Elevated Intraocular PressureCompletedPhase 2Can-Fite BioPharmaNCT01033422Written as CF101
- Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis SiccaCompletedPhase 2Can-Fite BioPharmaNCT00349466Written as CF101
- Piclidenoson for Treatment of COVID-19CompletedPhase 2Can-Fite BioPharmaNCT04333472Written as Piclidenoson
- CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid ArthritisTerminatedPhase 3Can-Fite BioPharmaNCT02647762Written as CF101 1 mg
- Trial of CF101 to Treat Patients With PsoriasisCompletedPhase 2/3Can-Fite BioPharmaNCT01265667Written as CF101
- Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis PatientsCompletedPhase 2Can-Fite BioPharmaNCT00556894Written as CF101
- A Study of the Efficacy and Safety of CF101 to Patients With Osteoarthritis of the KneeWithdrawnPhase 2Can-Fite BioPharmaNCT00837291Written as CF101
- Safety &Efficacy of CF101 to Subjects With UveitisWithdrawnPhase 2Can-Fite BioPharmaNCT01905124Written as CF101